Lazabemide

Lazabemide

Lazabemide

Chemical compound

Lazabemide (proposed trade names Pakio, Tempium) is a reversible and selective inhibitor of monoamine oxidase B (MAO-B) that was under development as an antiparkinsonian agent but was never marketed.[1]

Quick Facts Clinical data, Routes ofadministration ...

References

  1. [1]
    Henriot S, Kuhn C, Kettler R, Da Prada M (1994). "Lazabemide (Ro 19-6327), a reversible and highly sensitive MAO-B inhibitor: Preclinical and clinical findings". In Tipton KF, Youdim MB, Barwell CJ, Callingham BA, Lyles GA (eds.). Amine Oxidases: Function and Dysfunction. Proceedings of the 5th International Amine Oxidase Workshop, Galway, Ireland, August 22–25, 1992. Journal of Neural Transmission. Supplementum. Vol. 41. pp. 321–325. doi:10.1007/978-3-7091-9324-2_42. ISBN 978-3-211-82521-1. PMID 7931245.


Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.
Share this article:

This article uses material from the Wikipedia article Lazabemide, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.